<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724031</url>
  </required_header>
  <id_info>
    <org_study_id>P420_PARP</org_study_id>
    <nct_id>NCT04724031</nct_id>
  </id_info>
  <brief_title>Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer</brief_title>
  <official_title>Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced&#xD;
      high grade ovarian cancer who will receive PARP inhibitors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective-retrospective analysis of patients with histologically confirmed high grade&#xD;
      ovarian cancer who will receive or received olaparib or niraparib will be conducted at any&#xD;
      line of treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Progression Free Survival</measure>
    <time_frame>12/2022</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety profile of olaparib in women with advanced high grade ovarian cancer</measure>
    <time_frame>12/2021</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety profile of niraparib in women with advanced high grade ovarian cancer</measure>
    <time_frame>12/2021</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>One cohort</arm_group_label>
    <description>women with advanced epithelial ovarian cancer who received PARP inhibitors at any line of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PARP inhibitor</intervention_name>
    <description>use at any line of treatment in patients with advanced ovarian cancer</description>
    <arm_group_label>One cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        women with advanced high grade ovarian cancer who receive Parp inhibitors at any line of&#xD;
        treatmen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - women &gt;18 years old with advanced high grade ovarian cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female with ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Adamantia Nikolaidi</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>15321</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

